113% ROI on Large Enterprise Crowdsourcing Programs - Forrester TEI™ Get the Study ×

Prostate Cancer Foundation Stupski Prize Challenge – Computational Oncology

The Data Science Team at Topcoder is proud to announce a new partnership with the Prostate Cancer Foundation. This exciting collaboration will result in some of the most inspiring, challenging, and game-changing marathon match competition(s) we’ve ever put to the community. We anticipate the first match will launch in September, so be on the alert for the exciting news to come!

Prostate cancer is the second most common cancer in US men and the 4th most common tumor diagnosed worldwide. In 2015 alone, it is estimated that over 220,000 US men will be diagnosed with prostate cancer, and more than 27,000 will die from the disease.

Currently, prostate cancer is diagnosed by tissue biopsy. Pathologists examine tissue samples under a microscope and classify them with respect to certain characteristics (e.g., cancerous, benign, cancer type, cancer stage). Physicians make clinical decisions on the basis of those classifications.

Recent advances in biotechnology have made genomic data relatively cheaper to obtain, and emerging studies suggest that this information can–and should–be used to deliver precision medicine to every unique patient.

Bridging the gap between “big data” molecular datasets and individual patients poses critical question: is it possible to predict the genetic characteristics of a tumor using a high grade images of a biopsies, obviating the need to do genetic sequencing altogether? Help us find out by participating in the Stupski Prize Challenge 1.

Background on Prostate Cancer Foundation Stupski Prize in Computational Oncology:

The Prostate Cancer Foundation (PCF) is pleased to announce the Stupski Prize in Prostate Cancer Computational Oncology, a first-in-field initiative designed to attract novel ideas to the rapidly changing field of large-scale cancer bioinformatics. These solutions will help clinicians and researchers optimize treatment for individual prostate cancer patients and may also lead to breakthroughs in other cancers as common molecular drivers and pathways are uncovered.